HCmed Innovations is redefining how medicines reach patients around the world.

As a publicly listed med-tech company on the Taiwan Stock Exchange (TWSE: 6934), HCmed collaborates with pharmaceutical and biotech leaders to deliver inhalation therapies enabled by mesh nebulization—technologies that are not only innovative, but already supporting approved treatments in multiple regions, including the delivery of Pulmozyme in collaboration with Genentech.

At HCmed, inhalation is not just a delivery method. It is a therapeutic gateway that connects engineering, formulation science, and real-world patient impact.

What defines HCmed is the role we play in turning complex drug concepts into practical therapies that reach the market. Our work sits at the intersection of innovation, partnership, and world-class manufacturing, where ideas become products used in patient care today.

HCmed offers a unique platform for people who want to contribute to meaningful global healthcare innovation, work across borders, and be part of shaping the future of inhalation therapy.